Comparative evaluation of a dual-target real-time RT-PCR assay for COVID-19 diagnosis and assessment of performance in pooled saliva and nasopharyngeal swab samples

Cyril C. Y. Yip a, Kit-Hang Leung a, Anthony C. K. Ng b, Kwok-Hung Chan b, Kelvin K. W. To c,d,e, Jasper F. W Chan c,d,e, Ivan F. N. Hung f, Vincent C. C. Cheng a and Siddharth Sridhar a,c,d,e

aDepartment of Microbiology, Queen Mary Hospital, Hong Kong Special Administrative Region, China; bDepartment of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; cDepartment of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China; dState Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; eCarol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; fDepartment of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China

ABSTRACT

Objectives: Sensitive molecular diagnostic assays are essential for COVID-19 diagnosis. We evaluated the Hecin Scientific SARS-CoV-2 nucleic acid test kit, a dual-target real-time RT-PCR assay targeting the SARS-CoV-2 N and ORF1ab genes.

Methods: The Hecin test kit’s diagnostic performance in detecting SARS-CoV-2 RNA was compared to the LightMix Modular SARS and Wuhan CoV E-gene kit (TIB Molbiol) and an in-house single-tube nested real-time RT-PCR using 296 clinical specimens, 11 proficiency testing samples, and 30 low-positive deep throat saliva and nasopharyngeal swab (NPS) samples pooled into negative samples in ratios of 1:5, 1:10, and 1:30.

Results: The limit-of-detection of the Hecin test kit was around 500 dC/mL for the N and ORF1ab targets. Sensitivity and specificity of the Hecin test kit were 98.1% (95% CI: 93.4–99.8%) and 100% (98.1–100%), respectively, when measured against the reference method. The Hecin test kit showed fair sensitivity (80%) in low-positive NPS samples pooled in ratios of 1:5 and 1:10. Its performance in pooled samples could be dramatically improved by adjusting the assay Ct cutoff.

Conclusion: The Hecin test kit enables sensitive and specific detection of SARS-CoV-2 in clinical samples and pooled samples.

1. Introduction

Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a newly emerged betacoronavirus [1,2]. COVID-19 has affected human life and activity more than any other pandemic in modern history. As of 27 April 2021, there have been 146 million confirmed COVID-19 cases, of which 3 million people have died (https://www.who.int/emergencies/diseases/novel-coronavirus-2019), although actual numbers of affected individuals are likely much higher. SARS-CoV-2 RNA detection by real-time reverse-transcription polymerase chain reaction (RT-PCR) is the most commonly used diagnostic tool for COVID-19 [3–6]. Sensitive SARS-CoV-2 RT-PCR assays are not only important for patient diagnosis, but also facilitate community-level outbreak control and containment [7]. There is increased demand globally for RT-PCR reagents, which has raised the threat of shortage, especially for low- and middle-income countries [8,9]. One approach to tackle this problem is to pool samples together for extraction followed by RT-PCR testing [10]. Pool positivity would then trigger testing of individual samples. Concerns of reduced sensitivity with pooling have been raised and mathematical algorithms for calculating optimal pool size have been proposed [11–13]. Furthermore, the best sample types and optimal RT-PCR assay design for pooled testing are unknown. This study had two objectives: we first evaluated the performance of a novel dual-target commercial kit for COVID-19 diagnosis and compared its performance to the LightMix E-gene kit and our previously validated in-house single-tube nested (STN) COVID-19 N RT-PCR assay [14,15]. We then examined the sensitivity of pooled testing of paired nasopharyngeal swab (NPS) and deep throat saliva samples in a range of pool sizes using three RT-PCR assays.
2. Patients and methods

2.1. Viruses, clinical specimens, and proficiency samples for evaluation

Serial twofold dilutions of total nucleic acid (TNA) extracted from a Qnostics SARS-CoV-2 Medium Q Control (RANDOX, UK) were used for analytical sensitivity or limit-of-detection (LOD) evaluation. Different concentrations of TNA extracted from a SARS-CoV-2 culture isolate stock \((1.8 \times 10^7 \text{ TCID}_{50}/\text{mL})\) isolated from the nasopharyngeal aspirate (NPA) of a patient with COVID-19 in Hong Kong were used for imprecision evaluation [16-18]. Each concentration was tested in triplicate in single run for intra-assay, and tested over two independent runs (each run with triplicate) for inter-assay imprecision evaluation. TNAs extracted from a clinical respiratory specimen positive for human coronavirus HKU1 (HCoV-HKU1) and 17 culture isolates of SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, influenza A (H1N1)pdm09 and H3N2) viruses, influenza B virus, influenza C virus, respiratory syncytial virus, human metapneumovirus, parainfluenza virus types 1–4, human rhinovirus, and human adenovirus were used for analytical specificity evaluation [19].

For diagnostic performance evaluation, we retrieved 296 clinical specimens obtained for initial diagnostic evaluation of hospitalized patients with suspected COVID-19. These included 255 respiratory tract specimens (NPA, NPS, throat swab, deep throat saliva or sputum) and 41 non-respiratory specimens (conjunctival swab, rectal swab, or stool). The male: female ratio was 136:160 and patients’ median age was 59.5 years (range: 3 months – 99 years). Some of these specimens were previously used in other assay evaluations published by our group [14,15,20]. In addition to clinical specimens, three proficiency testing (PT) samples from College of American Pathologist (CAP) and eight PT samples from Quality Control for Molecular Diagnostics (QCMD) with different concentrations of SARS-CoV-2 or negative for SARS-CoV-2 were also evaluated.

To evaluate the practicality of pooling clinical specimens for COVID-19 diagnosis and deep throat saliva as an alternate specimen type for pooling, we selected 15 paired NPS and saliva specimens obtained on the same day from 15 hospitalized patients with confirmed COVID-19. Each positive specimen had a low viral load (defined as Ct > 30 by the LightMix E-gene kit, which is the test used in routine clinical practice in our laboratory) and was pooled with SARS-CoV-2-negative specimens in three different ratios (5 pooled in 1, 10 pooled in 1, and 30 pooled in 1). For example, pool of 5 indicates one positive sample spiked into four negative samples. For all three pooling ratios, 50 μL of each sample were added in each pool, and 250 μL of each well-mixed pool was subjected to TNA extraction. These pooled samples were evaluated by three different real-time RT-PCR assays as described below. The present study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW 20–286).

2.2. Nucleic acid extraction

We performed TNA extraction on clinical specimens, pooled samples, PT samples, and virus culture isolates using the NucliSSENS easyMAG extraction system (bioMérieux, Marcy-l’Étoile, France) as previously described [21]. Briefly, 250 μL of each sample was added into a lysis buffer, and 55 μL of eluate was obtained and stored at −80°C until use.

2.3. Real-time RT-PCR assays for SARS-CoV-2 RNA detection

The performance of a commercial dual-target SARS-CoV-2 nucleic acid test kit (Hecin Scientific, Inc., Guangdong, China) was evaluated in the present study. The Hecin test kit is a dual-target real-time RT-PCR assay that can detect the N and ORF1ab regions of SARS-CoV-2 and a human gene target as an internal control [22]. Each 20 μL reaction mixture contained 5 μL of SARS-CoV-2 amplification reaction solution 1 (primers, probes, PCR reaction buffer, and dNTPs), 5 μL of SARS-CoV-2 amplification reaction solution 2 (enzyme mixture), and 10 μL of TNA as the template. Amplification and detection were performed using LightCycler 96 Real-Time PCR System (Roche, Basel, Switzerland). FAM, VIC and Texas Red channels were chosen for detection of SARS-CoV-2 N-gene target, SARS-CoV-2 ORF1ab target, and human gene (as internal control), respectively. The thermocycling condition was 48°C for 5 min, 94°C for 2 min, and 45 cycles of 94°C for 10 s and 60°C for 35 s. The test kit consisted of a SARS-CoV-2 positive control (pseudoviral particles including ORF1ab and N gene target sequences) and a negative control (inactivated human cell culture) that were subjected to TNA extraction for monitoring the assay performance. For the resulting interpretation, samples are regarded as positive when Ct ≤ 37 for both N and ORF1ab, while samples are regarded as highly suspected positive when one gene target with Ct ≤ 37 and another gene target with Ct > 37 or undetermined. Repeated testing is recommended for these samples. If the results in the repeated testing showed that both gene targets were positive or either target was positive (Ct ≤ 37), then the samples are confirmed to be true positive. Samples are regarded as negative when Ct > 37 or undetermined for both gene targets and Ct ≤ 37 for internal control according to manufacturer’s instructions.

Two validated comparator real-time RT-PCR assays for SARS-CoV-2 detection were used in this study. LightMix Modular SARS and Wuhan CoV E-gene kit (TIB Molbiol, Berlin, Germany) with LightCycler Multiplex RNA Virus Master (Roche) was used as we previously described [14] and was designated as the reference method. Briefly, each 20 μL reaction mixture contained 4 μL of Roche Master, 0.5 μL of reagent mix, 0.1 μL of RT Enzyme, 5.4 μL of water, and 10 μL of TNA as the template. RT-PCR was performed using the LightCycler 480 II Real-Time PCR System (Roche). The thermocycling condition consisted of 55°C for 5 min, 95°C for 5 min, followed by 45 cycles of 95°C for 5 s, 60°C for 15 s, and 72°C for 15 s.
The second assay is an in-house developed STN real-time RT-PCR assay targeting the SARS-CoV-2 N gene was performed using QuantiNova Probe RT-PCR Kit (QIAGEN, Hilden, Germany) on LightCycler 480 II Real-Time PCR System (Roche) previously described by us [15]. This assay format maximizes sensitivity by combining two PCR reactions within a single reaction vessel. Each 20 μL reaction mixture contained 10 μL of 2x QuantiNova Probe RT-PCR Master Mix, 0.2 μL of QN Probe RT-Mix, 0.16 μL of each 10 μM outer forward and reverse primer, 1.6 μL of each 10 μM inner forward and reverse primer, 0.4 μL of 10 μM probe, 0.88 μL of nuclelease-free water and 5 μL of TNA as the template. The thermocycling condition was 95°C for 10 min, 95°C for 5 min, followed by 20 cycles of 95°C for 5 s and 69°C for 30 s, and then 40 cycles of 95°C for 5 s and 55°C for 30 s. The comparison of the characteristics of the three assays is summarized in Table S1.

2.4. Statistical analysis

Probit regression analysis was used to determine the detection limit of the Hecin test kit. Fisher’s exact test was used to compare the performance of the assays or the detection rates between NPS and saliva for each pooling size. Spearman’s correlation was used to assess the relation between the Ct values of different real-time RT-PCR assays. Ct values obtained from different assays or different pooling sites of each specimen type were compared using ANOVA Friedman test with Dunn’s multiple comparison tests (a Ct value of 41 was assigned to specimens that tested negative in the real-time RT-PCR assays). Ct values obtained from paired NPS and saliva pooled samples were compared using t test (Wilcoxon matched-pairs signed rank test). P < 0.05 was considered statistically significant. All statistical analyses were performed using GraphPad PRISM 8 or SPSS 26.0.

3. Results

3.1. Analytical performance of the Hecin test kit for SARS-CoV-2 detection

The LOD of the Hecin test kit was 528 dC/mL (95% CI: 313–1855 dC/mL) for N gene target and 532 dC/mL (95% CI: 347–1565 dC/mL) for ORF1ab target of SARS-CoV-2 (Table S2). For analytical specificity, the N and ORF1ab assays of the Hecin test kit did not cross-react with the above-mentioned respiratory viruses including human coronaviruses, indicating that the assays were specific to SARS-CoV-2. The intra- and inter-assay variations of the samples by the Hecin test kit were evaluated using different concentrations of TNA extracted from the SARS-CoV-2 isolate, the total imprecision (% CV) values ranged from 0.31% to 1.00% (Table S3).

3.2. Diagnostic performance of the Hecin test kit for SARS-CoV-2 detection

To assess the diagnostic performance of the Hecin test kit in clinical specimens, 296 initial clinical specimens from patients with suspected COVID-19 were subjected to SARS-CoV-2 detection by the Hecin test kit and two other RT-PCR assays: the LightMix E-gene kit and our in-house developed STN COVID-19-N RT-PCR assay. Among the 296 specimens, 105 (35.5%) were positive for SARS-CoV-2 by the Hecin test kit, while 107 (36.1%) and 106 (35.8%) were positive for SARS-CoV-2 by the LightMix E-gene kit and the in-house STN COVID-19-N RT-PCR assay, respectively (Table 1). There was no significant difference in the detection rate between the Hecin test kit and the comparator assays (P > 0.05). Using the LightMix E-gene assay as the reference method, the diagnostic sensitivity and specificity of the Hecin test kit were 98.1% (95% CI: 93.4–99.8%) and 100% (98.1–100%), respectively, while those of the in-house STN COVID-19-N assay were 99.1% (95% CI: 94.9–99.9%) and 100% (98.1–100%), respectively (Table 2). Two clinical specimens that showed discordant results had low viral load: 1) one saliva tested positive by the LightMix E-gene kit (Ct: 36.84) and the STN COVID-19-N assay (Ct: 29.69) was negative by the Hecin test kit and 2) one NPS tested positive by the LightMix E-gene kit (Ct: 34.87) was negative by the Hecin test kit and the STN COVID-19-N assay.

| Specimen type* (No. of specimens) | Number of positive results (%) | In-house STN COVID-19-N assay | P-value1 |
|----------------------------------|-------------------------------|------------------------------|----------|
| Hecin assay                      | LightMix E-gene assay         |                               |          |
| Respiratory tract:               |                               |                              |          |
| NPA/NPS/TS (128)                 | 60 (46.9)                     | 60 (46.9)                    | NS       |
| Saliva (122)                     | 35 (28.7)                     | 36 (29.5)                    | NS       |
| Sputum (5)                       | 0 (0)                         | 0 (0)                        | NS       |
| Non-respiratory tract:           |                               |                              |          |
| Conjunctival swab (23)           | 3 (13.0)                      | 3 (13.0)                     | NS       |
| Rectal swab/stool (18)           | 7 (38.9)                      | 7 (38.9)                     | NS       |
| Total (296)                      | 105 (35.5)                    | 106 (35.8)                   | NS       |

*Abbreviations: NPA, nasopharyngeal aspirate; NPS, nasopharyngeal swab; TS, throat swab
1NS, not significant

Table 2. Clinical performance comparison of the Hecin test kit and the in-house STN COVID-19-N assay with the LightMix E-gene assay as the reference method.

| Molecular assays          | LightMix E-gene assay | Sensitivity (95% CI) | Specificity (95% CI) |
|---------------------------|-----------------------|----------------------|----------------------|
| Hecin test kit            | Positive 105          | 98.1% (93.4–99.8%)   | 100% (98.1–100%)     |
|                           | Negative 2            | 99.1% (94.9–99.9%)   | 100% (98.1–100%)     |
| STN COVID-19-N assay      | Positive 106          | 99.1% (94.9–99.9%)   | 100% (98.1–100%)     |
|                           | Negative 1            | 100% (98.1–100%)     |                      |
(Table S4). Among 105 specimens tested SARS-CoV-2-positive by the Hecin test kit, 7 (6.7%) showed sole positivity for the N-gene target (n = 5, Ct: 33.64–35.81) or ORF1ab-gene target (n = 2, Ct: 28.64–34.55) upon repeat testing, thereby fulfilling criteria for positivity according to manufacturer’s instructions (Table S4). Among the 296 specimens, all showed positive for internal control with Ct ranging from 16.73 to 34.57, except one SARS-CoV-2-positive rectal swab showed negative. Among the three PT samples from CAP and eight PT samples from QCMD, the Hecin test kit gave 100% correct results. Agreements between Ct values generated by the Hecin test kit (N and ORF1ab targets) and the LightMix E-gene kit were demonstrated by strong correlation (Spearman’s ρ = 0.9986; P < 0.0001) (Figure 1). The Ct values obtained from the Hecin test kit and the LightMix E-gene kit were also examined. The median Ct values (interquartile range, IQR) of the Hecin test kit N target (29.66, IQR 24.17–33.02) and ORF1ab target (30.08, IQR 24.98–33.38) were significantly higher than that of the LightMix E-gene assay (28.30, IQR 23.48–32.60) (P < 0.0001) (Figure 2). The Ct values of the STN COVID-19-N RT-PCR assay were not compared to the Hecin test kit due to the differences in assay format (nested vs non-nested, which would not enable a fair comparison).

3.3. Evaluation of pooled NPS and deep throat saliva samples using three COVID-19 RT-PCR assays

To evaluate pooling strategies for COVID-19 diagnosis, each positive sample with low viral load (Ct > 30) were spiked into negative samples at pooling ratios of 1:5, 1:10 and 1:30. For each pool size, 15 pools of NPS and 15 pools of saliva were tested by three COVID-19 RT-PCR assays (Table S5). When results were interpreted according to manufacturer instructions, the Hecin test kit had equivalent detection rates to the comparator assays for both NPS and saliva samples, except for the pool of 10 saliva samples (Table 3). The detection rates could achieve 80% in pools of 5 and 10 for NPS tested positive by Hecin test kit. In most pooling conditions and detection formats, NPS pools performed better than saliva (Table 3). We reasoned that the stringent manufacturer cutoff for the Hecin test kit (requiring a Ct < 37) was a disadvantage when testing pooled samples. Therefore, we examined the effect of adjusting the Ct cutoff of the Hecin test kit to 39. Indeed, upon adjustment of the Hecin test kit positivity cutoff Ct to 39 in either one target, the detection rate improved to >90% for both NPS and saliva samples pooled 1:5 (Table 3).

To evaluate the reduction in viral load after pooling a positive sample with negative samples in different ratios, Ct values of pooled NPS and saliva samples were compared with those of the individual samples tested by the LightMix E-gene kit. For NPS samples, the median Ct (IQR) of the individual samples by LightMix E-gene kit was 33.28 (30.96–35.65), which was significantly lower than those of the pools of 5 [35.6 (33.7–37.4)] (P = 0.0069), pools of 10 [36.73 (35.14–37.41)] (P = 0.0024) and pools of 30 [41 (34.98–41)] (P < 0.0001). For saliva samples, the median Ct (IQR) of individual samples by LightMix E-gene kit was 34.51 (32.86–35.76), which was significantly lower than those of the pools of 5 [36

![Figure 1. Correlation of the Ct values of the samples found positive for SARS-CoV-2 by the Hecin test kit and LightMix E-gene kit: (A) N target of Hecin kit vs E-gene kit, (B) ORF1ab target of Hecin kit vs E-gene kit and (C) N target vs ORF1ab target of Hecin kit.](image-url)
Table 3. Detection rates of the pooled NPS and deep throat saliva samples tested by three different COVID-19 RT-PCR assays.

| Pooling size | Specimen type (No. of pooled samples tested) | Hecin test kit (according to manufacturer’s instructions) | Hecin test kit (with a cutoff Ct = 39 in either target) | LightMix E-gene kit | STN COVID-19-N assay |
|--------------|--------------------------------------------|----------------------------------------------------------|------------------------------------------------------|---------------------|----------------------|
| Pool of 5    | NPS (15)                                   | 11 (73.3)                                                | 14 (93.3)                                            | 12 (80)             | 13 (86.7)            |
|              | Saliva (15)                                | 10 (66.7)                                                | 15 (100)                                             | 11 (73.3)           | 12 (80)              |
| Pool of 10   | NPS (15)                                   | 12 (80)                                                  | 14 (93.3)                                            | 14 (93.3)           | 12 (80)              |
|              | Saliva (15)                                | 6 (40)                                                   | 9 (60)                                               | 11 (73.3)           | 10 (66.7)            |
| Pool of 30   | NPS (15)                                   | 3 (20)                                                   | 11 (73.3)                                            | 7 (46.7)            | 7 (46.7)             |
|              | Saliva (15)                                | 6 (40)                                                   | 9 (60)                                               | 9 (60)              | 6 (40)               |

*Each pool contained one positive sample spiked into samples negative for SARS-CoV-2 (e.g. pool of 5 indicates one positive sample spiked into 4 negative samples).
test kit showed good diagnostic performance for COVID-19
diagnosis.

Among 105 specimens positive for SARS-CoV-2 by the Hecin test kit, most of them were positive for both N and
ORF1ab targets, while 7 were positive for either gene target. We
found that one specimen with moderate viral load (Ct: 28.64) was solely positive for the ORF1ab target but negative
for N target by the Hecin test kit, similar result was obtained
after repeated testing. This raises the possibility of mismatches
between the primer/probe sequences of the Hecin kit and the
N gene sequences of the SARS-CoV-2 isolates in this specimen.
Further investigation is warranted to determine if mutations
have occurred in the N gene of this SARS-CoV-2 isolate.

Pooling of clinical specimens is a cost-effective method for
screening of COVID-19 [10]. Pooling is particularly useful in
mass screening programs [24–26], which allows early identi-
fication of infected asymptomatic persons [27]. However,
pooling would certainly result in a lower detection rate for
samples with high Ct value compared to individual sample
testing. This is a disadvantage in settings where high-
sensitivity testing is desirable such as hospitals. In this
study, we evaluated pools of two sample types: NPS and
deep throat saliva, pooled in three different ratios using
different assays. Our main findings are that a) detection
rate of NPS pools generally tended to be better than saliva
pools, b) the dual-target Hecin assay was equivalent to single-
target assays including those utilizing nested formats in small
pool sizes and c) the detection rate of the Hecin test kit for
pooled samples could be improved by adopting a less string-
gent Ct cutoff, although this would result in some loss of
specificity. With regard to this last finding, we found that the
Hecin test kit cutoff criteria may result in a reduction in
detection rate for pooled samples. Therefore, we propose
using a modified cutoff Ct of 39 to maximize detection
rates. As individual samples in positive pools would be
retested by the same kit or another platform to identify the
positive sample, the impact of false-positives arising from this
adjusted cutoff can be minimized. As expected, we found that
detection rates dropped with larger pool sizes. However,
optimal pool size in real-life settings depends on the preva-
ience of SARS-CoV-2 infection and pooling of specimens is
particularly useful and cost-effective when the positive rate is
low (e.g. < 1%). Several studies demonstrated that a pool size
of 5 or 10 is optimal when expected COVID-19 prevalence
rate is around 5%, while a pool size of around 30 is optimal
for the prevalence rate of 0.1% [10–13]. Lohse et al. demon-
strated that Ct values of pools were lower than those of single
samples at pool sizes of 30 samples; they claimed that this
was probably because of the carrier effect of higher RNA
content in pools [27]. However, we could not replicate this
finding in our study, in which only two saliva samples in
the pool of 30 showed reduction in Ct values, while others
showed increase in Ct values or negative results when com-
pared to the corresponding single samples tested by the
LightMix E-gene kit. This could be due to random variation
in pooling of small volume samples or RT-PCR, which was also
noted by Lee et al. [28].

To date, only pooling of nasopharyngeal specimens or
saliva RNA was reported [24–27,29], but we have
demonstrated that pooling of saliva samples could be an
acceptable alternative when pool sizes are small. The median
Ct values of pooled NPS and saliva samples (in pool of 5 or 10)
were reduced by 2–4 when compared to those of individual
samples. Interestingly, for pools of 30, the median Ct values
of pooled saliva were similar to those of pooled samples in pools
of 5 or 10, while those of pooled NPS was reduced by >7 when
compared to individual NPS samples. No significant difference
in the detection rates between the pooled NPS and saliva
samples was noted in the pool of 5, in which 100% of pooled
saliva samples were tested positive by the Hecin test kit. In
a previous study by Pasomsub et al. [29], pooling of saliva RNA
showed good performance in SARS-CoV-2 detection, further
investigation is warranted to determine if sensitivity would be
higher when testing the mixed nucleic acids.

5. Conclusions

In summary, we have validated the performance of a dual-
target SARS-CoV-2 real-time RT-PCR assay and demonstrated
its performance in the detection of SARS-CoV-2 RNA in both
pooled NPS and deep throat saliva samples.

Acknowledgments

The authors acknowledge the kind generosity of Hecin Scientific Inc. for
providing the SARS-CoV-2 nucleic acid test kit used in this study. Hecin
had no role in the design and conduct of the study, in the collection,
analysis and interpretation of data, or in the preparation, review or
approval of the manuscript.

Funding

This study was partly supported by the donations of Richard Yu and Carol
Yu, the Shaw Foundation Hong Kong, May Tam Mak Mei Yin, Michael
Seak-Kan Tong, Hui Ming, Hui Hoy and Chow Sin Lan Charity Fund
Limited, Chan Yin Chuen Memorial Charitable Foundation, Marina Man-
Wai Lee, the Hong Kong Hainan Commercial Association South China
Microbiology Research Fund, the Jessie & George Ho Charitable
Foundation, Perfect Shape Medical Limited, Kai Chong Tong, and Tse
Kam Ming Laurence; and funding from the Consultancy Service for
Enhancing Laboratory Surveillance of Emerging Infectious Diseases and
Research Capability on Antimicrobial Resistance for Department of Health
of the Hong Kong Special Administrative Region Government. The fund-
ing sources had no role in the design and conduct of the study, in the
collection, analysis and interpretation of data, or in the preparation, review
or approval of the manuscript.

Declaration of interest

S Srisihar has received speaker’s honoraria from Abbott Laboratories Limited.
JFW Chan has received travel grants from Pfizer Corporation Hong Kong and
Astellas Pharma Hong Kong Corporation Limited, and was an invited speaker
for Gilead Sciences Hong Kong Limited and Lumines Corporation. These
parties had no role in the design of the study; in the collection, analyses, or
interpretation of data; in the writing of the manuscript, or in the decision
to publish the results. The authors have no other relevant affiliations or finan-
cial involvement with any organization or entity with a financial interest in or
financial conflict with the subject matter or materials discussed in the manu-
script apart from those disclosed.
Author contributions

CCY Yip and S Sridhar conceived the study design and drafted the paper. KH Leung and ACK Ng performed the experiment. CCY Yip, KH Chan, KKW To, JFW Chan, IFN Hung, VCC Cheng and S Sridhar were involved in analysis and interpretation of data. All authors agree to be accountable for all aspects of the work.

ORCID

Kelvin K. W. To https://orcid.org/0000-0002-1921-5824
Jasper F. W Chan https://orcid.org/0000-0001-6336-6657
Ivan F. N. Hung https://orcid.org/0000-0002-1556-2538
Siddharth Sridhar https://orcid.org/0000-0002-2022-8307

References

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

1. Zhu N, Zhang D, Wang W, et al. A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
2. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523.
3. Chu DKW, Pan Y, Cheng SMS, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin Chem. 2020;66(4):549–555.
4. Cormican VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000445.
5. Chan WM, Ip JD, Chu AW, et al. Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole genome sequencing. J Med Virol. 2020. DOI:10.1002/jmv.26140.
6. Yip CC, Ho CC, Chan JF, et al. Development of a novel, genome subtraction-derived, SARS-CoV-2-Specific COVID-19-nsp2 real-time RT-PCR assay and its evaluation using clinical specimens. Int J Mol Sci. 2020;21(7):2574.
7. Cheng VCC, Wong SC, Chen JHK, et al. Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong. Infect Control Hosp Epidemiol. 2020;41(5):493–498.
8. Chu AW, Chan WM, Ip JD, et al. Evaluation of simple nucleic acid extraction methods for the detection of SARS-CoV-2 in nasopharyngeal and saliva specimens during global shortage of extraction kits. J Clin Virol. 2020;129:104519.
9. Moreno-Contras J, Espinoza MA, Sandoval-Jaime C, et al. Saliva sampling and its direct lysis, an excellent option to increase the number of SARS CoV2 diagnostic tests in settings with supply shortages. J Clin Microbiol. 2020;58(10):e01659–20.
10. Abdalhamid B, Bider CR, McCutchen EL, et al. Assessment of specimen pooling to conserve SARS-CoV-2 testing resources. Am J Clin Pathol. 2020;153(6):715–718.
11. Aragón-Caqué D, Fernández-Salinas J, Larroze D. Optimization of group size in pool testing strategy for SARS-CoV-2: a simple mathematical model. J Med Virol. 2020. DOI:10.1002/jmv.25929
12. Cherif A, Grobe N, Wang X, et al. Simulation of pool testing to identify patients with coronavirus disease 2019 Under conditions of limited test availability. JAMA Network Open. 2020;3(6):e2013075.
13. Pilcher CD, Westreich D, Hudgens MG. Group testing for severe acute respiratory syndrome–coronavirus 2 to enable rapid scale-up of testing and real-time surveillance of incidence. J Infect Dis. 2020;222(6):903–909.

• Optimal sample pooling sizes were estimated at different levels of SARS-CoV-2 prevalence.
14. Yip CC, Sridhar S, Cheng AK, et al. Evaluation of the commercially available LightMix® Modular E-gene kit using clinical and proficiency testing specimens for SARS-CoV-2 detection. J Clin Virol. 2020;129:104476.
15. Yip CC, Sridhar S, Leung KH, et al. Development and evaluation of novel and highly sensitive single-tube nested real-time RT-PCR assays for SARS-CoV-2 detection. Int J Mol Sci. 2020;21(16):5674.

• A highly sensitive in-house developed RT-PCR assay for SARS-CoV-2 detection using a nested format within a single reaction vessel.
16. Chu H, Chan JF, Yuen TT, et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV: implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe. 2020;1(1):e14–e23.
17. Chan JF, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020;71(9):2428–2446.
18. Chu H, Chan JF, Wang Y, et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis. 2020;71(6):1400–1409.
19. Chan JF, Yip CC, To KK, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J Clin Microbiol. 2020;58(5):e00310–20.
20. Li X, Chan JF, Li KK, et al. Detection of SARS-CoV-2 in conjunctival secretions from patients without ocular symptoms. Infection. 2020. DOI:10.1007/s15010-020-01524-2.
21. Yip CC, Chan WM, Ip JD, et al. Nanopore sequencing reveals novel targets for detection and surveillance of human and avian influenza a viruses. J Clin Microbiol. 2020;58(5):e02127–19.
22. Iglói Z, Leven M, Abdel-Karem Abou-Nouar Z, et al. Comparison of commercial realtime reverse transcription PCR assays for the detection of SARS-CoV-2. J Clin Virol. 2020;129:104510.
23. Chen JH, Yip CC, Chan JF, et al. Clinical performance of the luminex NxTag CoV extended panel for SARS-CoV-2 detection in nasopharyngeal specimens from COVID-19 patients in Hong Kong. J Clin Microbiol. 2020;58(8):e00936–20.
24. Ben-Ami R, Klochendler A, Seidel M, et al. Large-scale implementation of pooled RNA extraction and RT-PCR for SARS-CoV-2 detection. Clin Microbiol Infect. 2020;26(9):1248–1253.
25. Kim SY, Lee J, Sung H, et al. Pooling upper respiratory specimens for rapid mass screening of COVID-19 by real-time RT-PCR. Emerg Infect Dis. 2020;26(10):2469–2472.
26. Yelin I, Aharony N, Shaer Tamar E, et al. Evaluation of COVID-19 RT-qPCR test in multi-sample pools. Clin Infect Dis. 2020;71(16):2073-2078..
27. Lohse S, Pfuhl T, Berkó-Göttel B, et al. Pooling of samples for testing for SARS-CoV-2 in asymptomatic people. Lancet Infect Dis. 2020;20(11):1231-1232.
28. Lee J, Kim SY, Sung H, et al. Challenges and issues of SARS-CoV-2 pool testing. Lancet Infect Dis. 2020;20(11):1233-1234.
29. Pasomsob E, Watcharananan SP, Watthanachokchai T, et al. Saliva sample pooling for the detection of SARS-CoV-2. J Med Virol. 2020. DOI:10.1002/jmv.26460.